---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-103622"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2023-04-17T23:59:59+00:00"
generated_at: "2026-06-17T01:26:39.595824+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Mirum prices $316.25M 4.00% convertible notes due 2029; repurchases $192.7M revenue interests

## Summary
- Issued $316.25M principal (incl. full exercise of $41.25M over-allotment) of 4.00% convertible senior notes due May 1, 2029.
- Initial conversion price ~$31.74/share, a 35% premium over $23.51 closing stock price on April 12, 2023.
- Net proceeds ~$305.4M; used ~$192.7M to repurchase revenue interests from Oberland Capital (RIPA) and terminate that agreement.
- Remaining proceeds expected for general corporate purposes, including working capital and potential acquisitions.
- Notes are senior unsecured; callable by Mirum after May 5, 2026 if stock price >130% of conversion price.

## SEC filing metadata
- accession: 0001193125-23-103622
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2023-04-17T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 1.02, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000119312523103622/0001193125-23-103622-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000119312523103622/d487416d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-103622
- JSON: https://secwatch.observer/filing/0001193125-23-103622.json
- Plain text: https://secwatch.observer/filing/0001193125-23-103622.txt

## Key facts
- Debt Financings
  Mirum Pharmaceuticals, Inc. incurred convertible notes of $316.25 million at 4.00% per annum maturing May 1, 2029.
  - Instrument: convertible notes
  - Principal: $316.25 million
  - Rate: 4.00% per annum
  - Maturity: May 1, 2029
  - Event: incurrence
  source text: On April 17, 2023, Mirum Pharmaceuticals, Inc. (the “Company”) issued $316.25 million principal amount of its 4.00% Convertible Senior Notes due 2029
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759425/000119312523103622/0001193125-23-103622-index.htm
- Material Agreements
  Mirum Pharmaceuticals, Inc. entered into Indenture with U.S. Bank Trust Company, National Association, as trustee valued at $316.25 million principal amount of its 4.00% Convertible Senior Notes due 2029 (effective 2023-04-17).
  - Action: entry
  - Agreement: notes offering
  - Counterparty: U.S. Bank Trust Company, National Association, as trustee
  - Value: $316.25 million principal amount of its 4.00% Convertible Senior Notes due 2029
  - Effective: 2023-04-17
  source text: On April 17, 2023, Mirum Pharmaceuticals, Inc. (the “Company”) issued $316.25 million principal amount of its 4.00% Convertible Senior Notes due 2029 (the “Notes”). The Notes were issued pursuant to, and are governed by, an indenture (the “Indenture”), dated as of April 17, 2023, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759425/000119312523103622/0001193125-23-103622-index.htm
- Material Agreements
  Mirum Pharmaceuticals, Inc. entered into Purchase Agreement with the initial purchasers of the Notes valued at $41.25 million principal amount of Notes.
  - Action: entry
  - Agreement: underwriting
  - Counterparty: the initial purchasers of the Notes
  - Value: $41.25 million principal amount of Notes
  source text: Pursuant to the purchase agreement among the Company and the initial purchasers of the Notes (the “Purchase Agreement”), the Company granted the initial purchasers an option to purchase, for settlement within a period of 13 days from, and including, the date the Notes are first issued, up to an additional $41.25 million principal amount of Notes.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759425/000119312523103622/0001193125-23-103622-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.